Patents by Inventor Richard William Versace

Richard William Versace has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Combinations of therapeutic agents for treating cancer
    Patent number: 8975248
    Abstract: A combination therapy for treating patients suffering from proliferative diseases or diseases associated with persistent angiogenesis is disclosed. The patient is treated with a camptothecin derivative and one or more chemotherapeutic agents selected from a microtubule active agent; an alkylating agent; an anti-neoplastic anti-metabolite; a platin compound; a topoisomerase II inhibitor; a VEGF inhibitor; a tyrosine kinase inhibitor; an EGFR kinase inhibitor; an mTOR kinase inhibitor; an insulin-like growth factor I inhibitor; a Raf kinase inhibitor; a monoclonal antibody; a proteasome inhibitor; a HDAC inhibitor; and ionizing radiation.
    Type: Grant
    Filed: December 13, 2005
    Date of Patent: March 10, 2015
    Assignee: Sigma-Tau Industrie Farmaceutiche Riunite S.p.A.
    Inventors: Sara Zaknoen, Margaret Ma Woo, Richard William Versace, Claudio Pisano, Loredana Vesci
  • COMBINATIONS OF THERAPEUTIC AGENTS FOR TREATING CANCER
    Publication number: 20120252811
    Abstract: The invention relates to a combination comprising a Bcr-Abl, c-Kit and PDGF-R tyrosine kinase inhibitor; and one or more pharmaceutically active agents; pharmaceutical compositions comprising said combination; methods of treatment comprising said combination; processes for making said combination; and a commercial package comprising said combination.
    Type: Application
    Filed: April 2, 2012
    Publication date: October 4, 2012
    Inventors: Gregory Peter Burke, Ronald Richard Linnartz, Paul W. Manley, Richard William Versace
  • COMBINATIONS OF THERAPEUTIC AGENTS FOR TREATING CANCER
    Publication number: 20120129881
    Abstract: A combination of an mTOR inhibitor compound with one or more pharmaceutically active agents, for simultaneous, concurrent, separate or sequential use for preventing or treating a proliferative disease.
    Type: Application
    Filed: August 26, 2011
    Publication date: May 24, 2012
    Inventors: Gregory Burke, Heidi Lane, Ronald Richard Linnartz, Richard William Versace
  • Combinations of Therapeutic Agents for Treating Cancer
    Publication number: 20110257206
    Abstract: The invention relates to a combination comprising a microtubule active agent; and one or more pharmaceutically active agents; pharmaceutical compositions comprising said combination; methods of treatment comprising said combination; processes for making said combination; and a commercial package comprising said combination.
    Type: Application
    Filed: April 26, 2011
    Publication date: October 20, 2011
    Inventors: Gregory Burke, Ronald Richard Linnartz, Paul M.J. McSheehy, Richard William Versace, Markus Wartmann
  • COMBINATION OF HISTONE DEACETYLASE INHIBITORS AND RADIATION
    Publication number: 20100311805
    Abstract: This invention relates to organic compounds of formula (I): in particular, to pharmaceutical compositions for use in combination with ionizing radiation for the delay of progression or treatment of a proliferative disease, especially a solid tumor disease.
    Type: Application
    Filed: August 9, 2010
    Publication date: December 9, 2010
    Applicant: NOVARTIS AG
    Inventor: Richard William Versace
  • COMBINATIONS OF THERAPEUTIC AGENTS FOR TREATING CANCER
    Publication number: 20100028338
    Abstract: A combination therapy for treating patients suffering from proliferative diseases or diseases associated with persistent angiogenesis is disclosed. The patient is treated with a camptothecin derivative and one or more chemotherapeutic agents selected from a microtubule active agent; an alkylating agent; an anti-neoplastic anti-metabolite; a platin compound; a topoisomerase II inhibitor; a VEGF inhibitor; a tyrosine kinase inhibitor; an EGFR kinase inhibitor; an mTOR kinase inhibitor; an insulin-like growth factor I inhibitor; a Raf kinase inhibitor; a monoclonal antibody; a proteasome inhibitor; a HDAC inhibitor; and ionizing radiation.
    Type: Application
    Filed: December 13, 2005
    Publication date: February 4, 2010
    Inventors: Sara Zaknoen, Margaret Ma Woo, Richard William Versace, Claudio Pisano, Loredana Vesci
  • COMBINATIONS COMPRISING BCR-ABL/C-KIT/PDGF-R TK INHIBITORS FOR TREATING CANCER
    Publication number: 20090233905
    Abstract: The invention relates to a combination comprising a Bcr-Abl, c-Kit and PDGF-R tyrosine kinase inhibitor; and one or more pharmaceutically active agents; pharmaceutical compositions comprising said combination; methods of treatment comprising said combination; processes for making said combination; and a commercial package comprising said combination.
    Type: Application
    Filed: April 4, 2007
    Publication date: September 17, 2009
    Inventors: Gregory Peter Burke, Ronald Richard Linnartz, Paul W. Manley, Richard William Versace
  • COMBINATIONS OF THERAPEUTIC AGENTS FOR TREATING CANCER
    Publication number: 20090098137
    Abstract: A combination of an mTOR inhibitor compound with one or more pharmaceutically active agents, for simultaneous, concurrent, separate or sequential use for preventing or treating a proliferative disease.
    Type: Application
    Filed: April 5, 2007
    Publication date: April 16, 2009
    Applicant: NOVARTIS AG
    Inventors: Gregory Burke, Heidi Lane, Ronald Richard Linnartz, Richard William Versace
  • COMBINATIONS OF THERAPEUTIC AGENTS FOR TREATING CANCER
    Publication number: 20090099103
    Abstract: The invention relates to a combination comprising an Erb-B and VEGF receptor inhibitor; and one or more pharmaceutically active agents; pharmaceutical compositions comprising said combination; methods of treatment comprising said combination; processes for making said combination; and a commercial package comprising said combination.
    Type: Application
    Filed: April 4, 2007
    Publication date: April 16, 2009
    Applicant: NOVARTIS AG.
    Inventors: Gregory Burke, Giorgio Caravatti, Heidi lane, Ronald richard Linnartz, Richard William Versace
  • Combination of Histone Deacetylase Inhibitors and Radiation
    Publication number: 20080319045
    Abstract: This invention relates to organic compounds of formula (I): in particular, to pharmaceutical compositions for use in combination with ionizing radiation for the delay of progression or treatment of a proliferative disease, especially a solid tumor disease.
    Type: Application
    Filed: October 23, 2006
    Publication date: December 25, 2008
    Applicant: NOVARTIS AG
    Inventor: Richard William Versace
  • Substituted Lactams and Their Use as Anti-Cancer Agents
    Publication number: 20080275025
    Abstract: This invention relates to certain substituted lactam compounds, particularly caprolactam compounds, which are useful for the treatment of cancer.
    Type: Application
    Filed: May 7, 2008
    Publication date: November 6, 2008
    Inventors: Kenneth Walter Bair, Frederick Ray Kinder, Richard William Versace
  • DEACETYLASE INHIBITORS
    Publication number: 20080176849
    Abstract: The present invention provides hydroxamate compounds which are deacetylase inhibitors. The compounds are suitable for pharmaceutical compositions having anti-proliferative properties.
    Type: Application
    Filed: March 11, 2008
    Publication date: July 24, 2008
    Inventors: Stacy William Remiszewski, Kenneth Walter Bair, Richard William Versace, Lawrence Blas Perez, Michael Alan Green, Lidia Cristina Sambucetti, Sushil Sharma
  • Substituted lactams and their use as anti-cancer agents
    Patent number: 7378410
    Abstract: This invention relates to certain substituted lactam compounds of the formula (I), particularly caprolactam compounds, which are useful for the treatment of cancer
    Type: Grant
    Filed: July 23, 2004
    Date of Patent: May 27, 2008
    Assignee: Novartis AG
    Inventors: Kenneth Walter Bair, Frederick Ray Kinder, Jr., Richard William Versace
  • Deacetylase inhibitors
    Patent number: 6833384
    Abstract: The present invention provides hydroxamate compounds which are deacetylase inhibitors. The compounds are suitable for pharmaceutical compositions having anti-proliferative properties.
    Type: Grant
    Filed: November 19, 2002
    Date of Patent: December 21, 2004
    Assignee: Novartis AG
    Inventors: Stacy William Remiszewski, Kenneth Walter Bair, Richard William Versace, Lawrence Blas Perez, Michael Alan Green, Lidia Cristina Sambucetti, Sushil Sharma
  • Use of certain substituted caprolactam carbonates and ethers in treating tumors
    Patent number: 6599898
    Abstract: The present invention relates to certain substituted caprolactam carbonate and ether compounds, pharmaceutical compositions containing said compounds, the use of said compounds in treating tumors and to a process for making said compounds.
    Type: Grant
    Filed: May 17, 2002
    Date of Patent: July 29, 2003
    Assignee: Novartis AG
    Inventors: Frederick Ray Kinder, Jr., Richard William Versace, Kenneth Walter Bair
  • Use of certain substituted caprolactams in treating tumors
    Patent number: 6555533
    Abstract: The present invention relates to certain substituted caprolactam compounds, pharmaceutical compositions containing said compounds, the use of said compounds in treating tumors and to a process for making said compounds.
    Type: Grant
    Filed: March 12, 2001
    Date of Patent: April 29, 2003
    Assignee: Novartis AG
    Inventors: Frederick Ray Kinder, Jr., Kenneth Walter Bair, Christopher Turchik Jagoe, Richard William Versace, Sompong Wattanasin
  • Deacetylase inhibitors
    Patent number: 6552065
    Abstract: The present invention provides hydroxamate compounds which are deacetylase inhibitors. The compounds are suitable for pharmaceutical compositions having anti-proliferative properties.
    Type: Grant
    Filed: August 31, 2001
    Date of Patent: April 22, 2003
    Assignee: Novartis AG
    Inventors: Stacy William Remiszewski, Kenneth Walter Bair, Richard William Versace, Lawrence Blas Perez, Michael Alan Green, Lidia Cristina Sambucetti, Sushil Sharma
  • Certain substituted caprolactam carbonates and ethers, pharmaceutical compositions containing them and their use in treating tumors
    Publication number: 20030055041
    Abstract: The present invention relates to certain substituted caprolactam carbonate and ether compounds, pharmaceutical compositions containing said compounds, the use of said compounds in treating tumors and to a process for making said compounds.
    Type: Application
    Filed: May 17, 2002
    Publication date: March 20, 2003
    Inventors: Frederick Ray Kinder, Richard William Versace, Kenneth Walter Bair
  • Certain substituted caprolactam carbonates and ethers, pharmaceutical compositions containing them and their use in treating tumors
    Patent number: 6413954
    Abstract: The present invention relates to certain substituted caprolactam carbonate and ether compounds, pharmaceutical compositions containing said compounds, the use of said compounds in treating tumors and to a process for making said compounds.
    Type: Grant
    Filed: May 8, 2001
    Date of Patent: July 2, 2002
    Assignee: Novartis AG
    Inventors: Frederick Ray Kinder, Jr., Richard William Versace, Kenneth Walter Bair
  • Use of certain substituted caprolactams in treating tumors
    Publication number: 20010044433
    Abstract: The present invention relates to certain substituted caprolactam compounds, pharmaceutical compositions containing said compounds, the use of said compounds in treating tumors and to a process for making said compounds.
    Type: Application
    Filed: March 12, 2001
    Publication date: November 22, 2001
    Inventors: Frederick Ray Kinder, Kenneth Walter Bair, Christopher Turchik Jagoe, Richard William Versace, Sompong Wattanasin